Avalo Therapeutics (NASDAQ:AVTX) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Avalo Therapeutics (NASDAQ:AVTX) in a research note released on Tuesday morning, Marketbeat.com reports. The firm issued a buy rating and a $36.00 price objective on the stock.

A number of other equities research analysts also recently commented on the company. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Piper Sandler initiated coverage on Avalo Therapeutics in a report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. BTIG Research initiated coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Avalo Therapeutics Stock Performance

Shares of NASDAQ AVTX opened at $8.73 on Tuesday. Avalo Therapeutics has a 1 year low of $5.99 and a 1 year high of $34.46. The firm’s 50 day moving average price is $7.59 and its 200 day moving average price is $9.13.

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently modified their holdings of AVTX. BVF Inc. IL lifted its position in Avalo Therapeutics by 7.2% during the fourth quarter. BVF Inc. IL now owns 1,036,679 shares of the company’s stock valued at $7,703,000 after buying an additional 69,679 shares in the last quarter. Ikarian Capital LLC lifted its holdings in shares of Avalo Therapeutics by 1,673.0% during the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company’s stock valued at $9,218,000 after acquiring an additional 915,629 shares in the last quarter. RA Capital Management L.P. purchased a new stake in Avalo Therapeutics during the 3rd quarter worth $9,186,000. Affinity Asset Advisors LLC increased its holdings in Avalo Therapeutics by 1,123.9% in the 4th quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company’s stock valued at $4,092,000 after purchasing an additional 505,765 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in Avalo Therapeutics in the fourth quarter valued at about $817,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.